Psoriatic arthropathy: Where now?

Israel Medical Association Journal

Volumn 11, Issue 7, 2009, Pages 430-434

  Slobodin, Gleb ^a   Rosner, Itzhak ^a   Rozenbaum, Michael ^a   Boulman, Nina ^a   Kessel, Aharon ^a,b   Toubi, Elias ^a,b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Biologicals; Psoriatic arthropathy; Spondyloarthritides

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CLINICAL FEATURE; DACTYLITIS; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENTHESITIS; ENTHESOPATHY; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; HAND DISEASE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; FINGERS; HUMANS; NAIL DISEASES; TOES;

EID: 69249203892     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Taurog DJ. The spondyloarthritides. In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th edn. New York: McGraw Hill, 2005: 1998-9.
2. Blumberg BS, Bunim JJ, Calkins E, Pirani CL, Zvaifler NJ. ARA nomenclature and classification of arthritis and rheumatism. Arthritis Rheum 1964; 26: 93-7.
3. Pasero G, Marson P. The antiquity of psoriatic arthritis. 3. Clin Exp Rheumatol 2006; 24: 351-3.
4. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(Suppl II): ii14-17.
5. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in spondylarthropathies: a systematic literature review. Ann Rheum Dis 2008; 67: 955-9.
6. Slobodin G, Naschitz JE, Zuckerman E, et al. Aortic involvement in rheumatic diseases. Clin Exp Rheumatol 2006; 24(2 Suppl 41): S41-7.
7. Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008; 35: 877-82.
8. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78.
9. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003; 42: 1460-8.
10. Symmons DPM, Lunt M, Watkins G, et al. Developing classification criteria for peripheral joint psoriatic arthritis. Step 1. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard." J Rheumatol 2006; 33: 552-7.
11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR study group. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
12. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? Ann Rheum Dis 2006; 65(Suppl III): iii22-4.
13. McGonagle D, Lories RJU, Tan AL, Benjamin M. The concept of a "synovio entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-91.
14. Jiaravuthisan MM. Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
15. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986; 13: 586-92.
16. Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006; 33: 1315-19.
17. Tan al, Grainer AJ, Tanner SF, Emery P, McGonagle D. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 2006; 54: 1328-33.
18. Resnick D, Niwayama A. Psoriatic arthritis. In: Resnick D, Niwayama A, eds. Diagnosis of Bone and Joint Disorders, 2nd edn. Philadelphia: WB Saunders, 1988: 1171-99.
19. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptide in psoriatic arthritis. J Rheumatol 2005; 32: 511-15.
20. Alenius GM, Berglin E, Dahlquist SR. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006; 65: 398-400.
21. Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic asociations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rhematology 2005; 44: 1056-60.
22. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005; 64(Suppl II): ii3-8.
23. Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007; 57: 1560-3.
24. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7: R569-80.
25. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 (Suppl II): ii26-29.
26. Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol 2001; 166: 2878-86.
27. Daoussis D, Andonopoulos AP, Liossis SNC. Increased expresion of CD154 (CD40L) on stimulated T cells from patients with psoriatic arthritis. Rheumatology 2007; 46: 227-31.
28. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
29. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007; 19: 284-8.
30. Partsch G, Wagner E, Leeb BF, Broll H, Dunkey A, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998; 57: 691-3.
31. Kane D, FitzGerald O. Tumor necrosis factor alpha in psoriasis and psoriatic arthritis: a clinical, genetic and histopathologic perspective. Curr Rheumatol Rep 2004; 6: 292-8.
32. Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, FitzGerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993; 36: 893-900.
33. Canete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007; 66: 720-6.
34. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
35. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeartion and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthitis. Arhtiritis Res Ther 2006; 8: R15.
36. Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNF, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 2007; 212: 47-55.
37. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Shwartz EM. Mechanisms of TNF-alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31.
38. Turkiewicz AM, Moreland LW. Psoriatic arthritis. Current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007;5 6: 1051-66.
39. Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008; 10: 277-81.
40. Gladman DD, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005; 32: 11.